Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors. In nonsquamo…
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
Why does where you live still determine your lung cancer care?
A narrative review synthesizing evidence from guidelines and real-world studies describes persistent global disparities in access to molecul…
Where you live still decides if you get advanced lung cancer tests and treatments, creating a harsh reality where geography and income deter…